Natriuretic Peptide Testing in High-Risk Pregnancy: A Preventive Opportunity?

被引：6

作者：

Kumari M. ^{[1
]}

Tang W.H.W. ^{[1
]}

Maroo A.P. ^{[2
]}

机构：

[1] Department of Cardiovascular Medicine, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH

[2] Department of Cardiology, Fairview Hospital, 18099 Lorain Avenue, Suite 245, Cleveland, 44111, OH

来源：

Current Heart Failure Reports | 2014年 / 11卷 / 4期

基金：

美国国家卫生研究院;

关键词：

B-type natriuretic peptide; Heart failure; Peripartum cardiomyopathy; Preeclampsia; Pregnancy;

D O I：

10.1007/s11897-014-0228-2

中图分类号：

学科分类号：

摘要：

Natriuretic peptide testing has been widely utilized in the heart failure and cardiac patient population, but there is limited utilization during pregnancy. Patients with hypertensive diseases of pregnancy have been shown to experience elevation of circulating natriuretic peptide levels compared to normal pregnancies, especially in the setting of preeclampsia. Natriuretic peptide testing can be utilized in patients presenting with signs and symptoms suspicious of heart failure in order to rule out underlying cardiac causes. Meanwhile, monitoring natriuretic peptide levels in those with established heart diseases (both congenital and acquired) may facilitate careful management of cardiac status during the course of pregnancy. Further investigations in the judicious use of selected medications (particularly loop diuretics) in the setting of elevated natriuretic peptide levels are warranted. © 2014, Springer Science+Business Media New York.

引用

页码：471 / 476

页数：5

共 35 条

[1]

Clark S.L., Cotton D.B., Lee W., Et al., Central hemodynamic assessment of normal term pregnancy, Am J Obstet Gynecol, 161, 6, pp. 1439-1442, (1989)

[2]

Chapman A.B., Abraham W.T., Zamudio S., Et al., Temporal relationships between hormonal and hemodynamic changes in early human pregnancy, Kidney Int, 54, 6, pp. 2056-2063, (1998)

[3]

Regitz-Zagrosek V., Blomstrom Lundqvist C., Borghi C., Et al., ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC), Eur Heart J, 32, 24, pp. 3147-3197, (2011)

[4]

Ruys T.P., Roos-Hesselink J.W., Hall R., Et al., Heart failure in pregnant women with cardiac disease: data from the ROPAC, Heart, 100, 3, pp. 231-238, (2014)

[5]

Yancy C.W., Jessup M., Bozkurt B., Et al., 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, J Am Coll Cardiol, 62, 16, pp. e147-e239, (2013)

[6]

Correa de Sa D.D., Chen H.H., The role of natriuretic peptides in heart failure, Curr Heart Fail Rep, 5, 3, pp. 177-184, (2008)

[7]

Seong W.J., Kim S.C., Hong D.G., Koo T.B., Park I.S., Amino-terminal pro-brain natriuretic peptide levels in hypertensive disorders complicating pregnancy, Hypertens Pregnancy, 30, 3, pp. 287-294, (2011)

[8]

Sawada Y., Suda M., Yokoyama H., Et al., Stretch-induced hypertrophic growth of cardiocytes and processing of brain-type natriuretic peptide are controlled by proprotein-processing endoprotease furin, J Biol Chem, 272, 33, pp. 20545-20554, (1997)

[9]

Yan W., Wu F., Morser J., Wu Q., Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme, Proc Natl Acad Sci U S A, 97, 15, pp. 8525-8529, (2000)

[10]

Ichiki T., Huntley B.K., Heublein D.M., Et al., Corin is present in the normal human heart, kidney, and blood, with pro-B-type natriuretic peptide processing in the circulation, Clin Chem, 57, 1, pp. 40-47, (2011)

← 1 2 3 4 →